NCT01478737View on ClinicalTrials.gov

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

Intravitreal dexamethasone implant

Intravitreal Ozurdex after vitrectomy

PROCEDURE

Vitrectomy

Vitrectomy only

Trial Locations (1)

11282

St. Erik Eye Hospital, Stockholm

All Listed Sponsors
lead

Anders Kvanta

OTHER

NCT01478737 - Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter